Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Invested Capital (2021 - 2026)

Zentalis Pharmaceuticals has reported Invested Capital over the past 6 years, most recently at $182.7 million for Q1 2026.

  • For Q1 2026, Invested Capital fell 38.15% year-over-year to $182.7 million; the TTM value through Mar 2026 reached $182.7 million, down 38.15%, while the annual FY2025 figure was $216.2 million, 35.88% down from the prior year.
  • Invested Capital for Q1 2026 was $182.7 million at Zentalis Pharmaceuticals, down from $216.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $523.3 million in Q2 2023 and troughed at $182.7 million in Q1 2026.
  • A 5-year average of $366.7 million and a median of $382.6 million in 2024 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: increased 22.18% in 2023 and later tumbled 38.15% in 2026.
  • Year by year, Invested Capital stood at $434.0 million in 2022, then rose by 0.75% to $437.3 million in 2023, then dropped by 22.89% to $337.2 million in 2024, then tumbled by 35.88% to $216.2 million in 2025, then decreased by 15.51% to $182.7 million in 2026.
  • Business Quant data shows Invested Capital for ZNTL at $182.7 million in Q1 2026, $216.2 million in Q4 2025, and $252.9 million in Q3 2025.